Kwivik Therapeutics Partners with EirMed to Accelerate Product Commercialization
News provided by
Share this article
Share this article
FRISCO, Texas, Jan. 13, 2021 /PRNewswire/ -- Kwivik Therapeutics Inc ("Kwivik"), a medtech developer of disruptive technologies for respiratory and emergency medical markets today announced the Company has partnered with EirMed to accelerate commercialization of some of its therapeutics product lines.
O2Fast is a product of Kwivik Therapeutics. O2Fast is a safe and easy to use solution that produces medical oxygen from two dry, inert powders. This proprietary "oxygen from powder" process means the oxygen is generated on demand. There is no pressurized storage of oxygen. O2Fast provides up to 20 minutes of high flow oxygen, is simple to use and allows a lay person to render aid while waiting for first responders arrive on the scene. https://www.kwivikmedical.com/therapeutics